View My Profile

Dawn Lemanne, MD, MPH

Fellowship 2011 Summer
Oncology Working Group

Dawn Lemanne, MD, MPH, Assistant Clinical Professor of Medicine at the University of Arizona, is a Stanford-trained, board-certified medical oncologist. Her professional interests include translation of emerging principles of cancer evolution into the clinic, including adaptive therapy models to decrease treatment resistance, and manipulation of metabolism to augment conventional cancer treatment. Her clinic combines conventional therapies with interventions such as short-term fasting, macronutrient manipulation, hyperbaric oxygen, and brief exposure to temperature extremes. Her clinic's motto: Leave no stone unturned.

Dr. Lemanne has published in peer-reviewed journals, has authored textbook chapters in integrative oncology, and oversees production of the oncology modules within the Arizona Center for Integrative Medicine Fellowship. She is coauthor of the popular book “n of 1,” the story of a man’s Harvard-documented recovery from a form of leukemia using non-conventional methods. She holds degrees in biophysics, public health, medicine, and science writing from the University of California, Berkeley, the University of California, San Francisco, and Johns Hopkins University. She is a 2011 graduate of the AZCIM fellowship and was the first medical oncologist to serve on the faculty of Memorial Sloan Kettering’s integrative medicine service.

Dr. Lemanne is a leader in the Quantified Self movement. She is a proponent of rigorously designed single-subject studies that investigate the effectiveness of lifestyle interventions in chronic disease. She is head of the Independent Metabolic Research Group, a collaboration of health professionals investigating the effects of diet, exercise, sleep, and supplements on biomarkers relevant to malignancy and other chronic diseases. She is the founder of Oregon Integrative Oncology in Ashland, Oregon, where she currently practices.

A recent publication: A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea